Our investigation has revealed that targeting PPFIA1 and PARP1 in the miR-181a/PPFIA1/PARP1/NF-κB-P65/KIT axis could attain significant and durable anti-leukemic activity in CML. This evidence concerns the gene KIT and chronic myelogenous leukemia, BCR-ABL1 positive.